156 related articles for article (PubMed ID: 31365075)
1. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.
Kulengowski B; Burgess DS
Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
[TBL] [Abstract][Full Text] [Related]
3. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Lee SY; Gill CM; Nicolau DP;
J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
[TBL] [Abstract][Full Text] [Related]
4. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
Delgado-Valverde M; Portillo-Calderón I; Alcalde-Rico M; Conejo MC; Hidalgo C; Del Toro Esperón C; Pascual Á
Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):445-457. PubMed ID: 38157139
[TBL] [Abstract][Full Text] [Related]
5. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
[TBL] [Abstract][Full Text] [Related]
6. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
7.
Maraki S; Mavromanolaki VE; Stafylaki D; Scoulica E
J Chemother; 2023 Nov; 35(7):596-600. PubMed ID: 36705145
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
[TBL] [Abstract][Full Text] [Related]
9. 1,4,7-Triazacyclononane Restores the Activity of β-Lactam Antibiotics against Metallo-β-Lactamase-Producing
Somboro AM; Amoako DG; Osei Sekyere J; Kumalo HM; Khan R; Bester LA; Essack SY
Appl Environ Microbiol; 2019 Feb; 85(3):. PubMed ID: 30478231
[TBL] [Abstract][Full Text] [Related]
10.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
Young K; Painter RE; Raghoobar SL; Hairston NN; Racine F; Wisniewski D; Balibar CJ; Villafania A; Zhang R; Sahm DF; Blizzard T; Murgolo N; Hammond ML; Motyl MR
BMC Microbiol; 2019 Jul; 19(1):150. PubMed ID: 31272373
[TBL] [Abstract][Full Text] [Related]
12.
Huang YS; Chen PY; Chou PC; Wang JT
Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
Karlowsky JA; Lob SH; Siddiqui F; Polis T; Vallejo JL; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Jun; 6(3):dlae077. PubMed ID: 38799180
[TBL] [Abstract][Full Text] [Related]
15. The
Fröberg G; Ahmed A; Chryssanthou E; Davies Forsman L
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0052823. PubMed ID: 37671880
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
Liang R; Wang D; Hu M; Gu Y; Wang M; Hu D; Zhu M; Wang M
J Antibiot (Tokyo); 2023 Sep; 76(9):540-547. PubMed ID: 37217796
[TBL] [Abstract][Full Text] [Related]
17. Reviewing novel treatment options for carbapenem-resistant
Mackow NA; van Duin D
Expert Rev Anti Infect Ther; 2024; 22(1-3):71-85. PubMed ID: 38183224
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents-SMART 2018-21.
Karlowsky JA; Wise MG; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad149. PubMed ID: 38161963
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing
Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates.
Lim TP; Ho JY; Teo JQ; Sim JH; Tan SH; Tan TT; Kwa AL
Microorganisms; 2023 Aug; 11(9):. PubMed ID: 37764002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]